Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05888701` - "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.
Terminated	`NCT00594308` - In-Vivo Activated T-Cell Depletion to Prevent GVHD	N/A
Completed	`NCT00407303` - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Phase 1/Phase 2
Completed	`NCT03019666` - Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL	Phase 1
Active, not recruiting	`NCT02996773` - Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine	Phase 1
Recruiting	`NCT02991638` - Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers	Phase 3
Active, not recruiting	`NCT02722668` - UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep	Phase 2
Completed	`NCT02661035` - Allo HSCT Using RIC for Hematological Diseases	Phase 2
Recruiting	`NCT03314974` - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	Phase 2
Active, not recruiting	`NCT00878254` - Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma	Phase 2
Active, not recruiting	`NCT02267915` - Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT	Phase 2
Completed	`NCT00088205` - Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma	Phase 2
Completed	`NCT00186628` - Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD	Phase 2
Completed	`NCT03010982` - Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors	Phase 1
Completed	`NCT00783367` - Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas	Phase 2
Recruiting	`NCT00946374` - Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma	Phase 2
Completed	`NCT01474681` - Safety and Tolerability of HSC835 in Patients With Hematological Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT02631044` - Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)	Phase 1
Withdrawn	`NCT01163201` - T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT05868395` - Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma	Phase 2

NCT number	NCT03112174
Study type	Interventional
Source	Pharmacyclics LLC.
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	June 29, 2017
Completion date	November 15, 2024

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms